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Abstract Survival of glioblastoma patients has been
linked to the completeness of surgical resection. Available
data, however, were generated with adjuvant radiotherapy.
Data conﬁrming that extensive cytoreduction remains ben-
eﬁcial to patients treated with the current standard, con-
comitant temozolomide radiochemotherapy, are limited. We
therefore analyzed the efﬁcacy of radiochemotherapy for
patients with little or no residual tumor after surgery. In this
prospective, non-interventional multicenter cohort study,
entry criteria were histological diagnosis of glioblastoma,
small enhancing or no residual tumor on post-operative
MRI, and intended temozolomide radiochemotherapy. The
primary study objective was progression-free survival; sec-
ondary study objectives were survival and toxicity. Fur-
thermore, the prognostic value of O6-methylguanine-DNA
methyltransferase (MGMT) promoter methylation was
investigated in a subgroup of patients. One-hundred and
eighty patients were enrolled. Fourteen were excluded by
patient request or failure to initiate radiochemotherapy.
Twenty-three patients had non-evaluable post-operative
imaging. Thus, 143 patients qualiﬁed for analysis, with 107
patients having residual tumor diameters B1.5 cm. Median
follow-up was 24.0 months. Median survival or patients
without residual enhancing tumor exceeded the follow-up
period. Median survival was 16.9 months for 32 patients
with residual tumor diameters [0t oB1.5 cm (95% CI:
13.3–20.5, p = 0.039), and 13.9 months (10.3–17.5, overall
p\0.001) for 36 patients with residual tumor diameters
[1.5 cm. Patient age at diagnosis and extent of resection
were independently associated with survival. Patients with
MGMT promoter methylated tumors and complete resection
made the best prognosis. Completeness of resection acts
synergistically with concomitant and adjuvant radiochemo-
therapy, especially in patients with MGMT promoter
methylation.
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Introduction
Cytoreductive surgery for glioblastoma is generally
assumed to be beneﬁcial. However, data supporting this
assumption are based on studies evaluating the extent of
surgical resection in glioblastoma patients treated by
adjuvant radiotherapy [1–3]. In 2005, radiotherapy with
concomitant and adjuvant temozolomide was established
as the standard of care in glioblastoma after the EORTC
A list of participating surgeons is given in the Appendix.
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DOI 10.1007/s11060-012-0798-326981–22981/NCIC CE.3 trial [4, 5]. In this trial patients
with ‘‘complete’’ resections seemed to beneﬁt more than
those with ‘‘incomplete’’ resections [5]. However, radi-
cality was not assessed on the basis of imaging, but rather
on the judgement of the surgeon, which is known to
overestimate the extent of resection [6]. Therefore, the
concept that extensive cytoreductive surgery in glioblas-
toma is still necessary requires veriﬁcation in a study with
post-operative imaging, because the beneﬁts of adding
concomitant and adjuvant temozolomide to radiotherapy
might overcome beneﬁts derived from extensive resection,
with its inherent risks. On the other hand, it may also be
that cytoreduction of glioblastoma and removal of residual
tumor tissue might enhance the efﬁcacy of radiochemo-
therapy, thus acting synergistically [7].
We therefore performed a non-interventional cohort
study addressing this question, because a randomized study
with different degrees of resection would be unfeasible. To
minimize the effect of patient-dependent factors on the
extent of resection, we required investigators to include
patients with small residual contrast-enhancing tumor
remnants or no residual tumor. It has been demonstrated
[1, 6], that a number of patient-dependent factors may
affect the extent of resection, foremost age and Karnofsky
performance score (KPS). These factors, which affect
resection may also affect survival, and may confound
interpretation of data concerning the effect of resection on
outcome for retrospective patient cohorts.
Additionally, we assessed O6-methylguanine-DNA
methyltransferase (MGMT) promoter methylation status [8]
in a subset of patients to determine its interaction with
resection and outcome.
Patients and methods
Nineteen centers participated in this prospective, non-
interventional cohort study. The study included glioblas-
toma patients older than 18 years, without previous
tumor-speciﬁc therapy and without factors precluding
radiochemotherapy (hemoglobin C 10 g/dl, neutrophil gran-
ulocytes C 1.5 9 109/l, thrombocytes C 100 9 109/l).
Early post-operative MRI within 72 h after surgery was
required to be indicative of either no residual contrast-
enhancing tumor or only minimal residual tumor not
exceeding 1.5 cm in diameter (RECIST, http://www.recist.
com). RECIST assessments are easier to perform than vol-
umetric methods and have been reported to correlate with
overall survival similar to volumetric methods [9–11]).
To assess protocol adherence, MRIs were reviewed in a
blinded fashion by one of the authors (T.M.). If tumor
diameters were larger than 1.5 cm, patients were analyzed
separately. The safety analysis included all patients
documented in the study that had begun concomitant
radiochemotherapy, irrespective of whether an early post-
operative MRI was available.
Participating surgeons were asked to submit parafﬁn-
embedded tumor tissue samples for methylation-speciﬁc
PCR analysis of the MGMT promoter methylation [12]a n d
central histopathology review at the Brain Tumor Reference
Center of the German Society of Neuropathology and
Neuroanatomy in Du ¨sseldorf (G.R., J.F.). However, because
this was a non-interventional cohort study, submission of
tissue samples for reference pathology was not mandatory
and samples could not be collected from all patients.
Primary study objectives were to determine progression-
free survival overall and stratiﬁed by residual tumor
volumes based on MRI compared with a well-deﬁned
historical cohort of patients with surgery and radiotherapy
[1]. Secondary study objectives were to determine overall
survival (last assessment 12 months after recruitment of
last patient) and toxicity according to CTC criteria.
Therapy data were collected until radiographic tumor
progression or until six cycles of adjuvant temozolomide
were completed. Follow-up MRIs were performed at three-
monthly intervals or at clinical deterioration until radio-
logical progression. Progression was deﬁned as an increase
of enhancing tumor diameter by 25% or the appearance of
new contrast-enhancing lesions. Survival data, deﬁned as
the time between resection and death, were collected for all
patients. Patients alive at the time of ﬁnal analysis were
censored at the date of last patient contact.
Patients with available MGMT promoter methylation
data and early post-operative MRI were stratiﬁed according
to the extent of resection and MGMT status for assessing
the combined effect of both of these on survival.
Concomitant radiochemotherapy followed by temozol-
omide chemotherapy was performed according to the cur-
rent standard of care. During the concomitant phase
patients were treated by radiotherapy (58–60 Gy, daily
fractions: 2 Gy) with temozolomide at a dose of 75 mg/m
2/
day. Approximately four weeks after completion of
radiotherapy, monotherapy with temozolomide was initi-
ated, beginning with 150 mg/m
2 per day for ﬁve of 28 days
during the ﬁrst cycle, thereafter, if tolerated, with 200 mg/
m
2 during ﬁve of 28 days for a total of six cycles.
Biometry and statistical methods
The sample size was determined to detect a 30% increase
of PFS of the entire group of patients compared with the
known PFS of approximately 6 months [1] for the cohort
operated on with 5-ALA in the ALA study [1] (with 65%
complete resections and adjuvant radiotherapy), under the
assumption that resection success would be similar in our
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123cohorts, i.e. to detect a PFS of 7.8 months. The type 1 error
was 0.05 (two-sided), the type 2 error 0.20, recruitment
time 2 years, minimum follow up 1 year, and assumed
drop out 25%. Thus, 180 patients had to be recruited to
obtain 135 evaluable patients. Sample size was estimated
by use of a self-written program implementing the
Schoenfeld–Richter nomogram [13].
Univariate statistical analysis was performed using
Kaplan–Meier estimates and log rank tests. Multivariable
Cox proportional hazards models were used where appli-
cable. Statistical evaluation was performed using SPSS
software version 15.
Data collection was performed by Clinstud CRO,
Wedel, Germany, and data analysis by the Department of
Biometry and Clinical Epidemiology, Charite ´ Berlin (P.M.,
O.J.). Patients gave informed consent, as required by local
ethics review committees in this non-interventional study
and all data were entered into anonymous case report forms
by local co-investigators before being collected by the
study ofﬁce. Because this was a non-interventional cohort
study, no source data veriﬁcation was performed by
monitors.
Patient cohorts
Patients were recruited between May 2006 and October
2007. Of 180 patients initially reported to the study
ofﬁce, fourteen patients who did not go on to have
radiochemotherapy were excluded from the analysis
(one patient refused to participate further, for eight
patients progression occurred before the start of adjuvant
therapy, four patients refused adjuvant therapy, and one
patient suffered complicating sigmadiverticulitis pre-
cluding radiochemotherapy).
Early post-operative imaging was performed for the
remaining 166 patients. For 23 patients, however, the MR
images were not evaluable for residual contrast-enhancing
tumor by the reference radiologist (missing t1 without
contrast, n = 6; missing t1 with contrast, n = 6; unen-
hanced CT only, n = 3; no MRI available, n = 2; cavity
obscured by hemorrhage, n = 1; pre-OP missing with
ambiguous post-OP MRI because of hemorrhagic changes,
n = 1; bihemispheric lesions, n = 1, images not obtainable
for reference assessment, n = 3). These patients were
included in the safety analysis set only. Thus, a total of 143
patients had evaluable early post-operative MRI and
concomitant therapy. Of these, 75 patients had no residual
contrast-enhancing tumor, 32 patients had residual tumor
with a diameter of[0 to 1.5 cm, and 36 patients had a
residual tumor load[1.5 cm in diameter. MGMT promoter
methylation status could be determined in 79 of the 143
patients (55%) with evaluable early post-operative MRI.
Mean tumor diameter for patients with residual tumor
was 1.07 ± 0.35 cm (SD, range 0.3–1.5; median 1.1 cm).
For patients with tumors[1.5 cm, the mean diameter of
residual tumor tissue was 2.7 cm (±1.1 cm, median
2.4 cm, range 1.6–7.1 cm).
Results
Safety
The characteristics of patients entered into the safety
analysis, including toxic adverse events, are provided in
Supplementary Table 1.
Overall outcome
Median progression-free survival for all 143 patients with
evaluable post-operative MRI was 10.4 months (95% CI:
8.1–12.8 months). Thus the primary analysis according to
the statistical design—prolongation of PFS longer than
6 months as determined by the lower conﬁdence limit—
was successful. Overall survival was 19.4 months (95%
CI: 15.6–23.3 months). If those patients with non-evalu-
able or missing early post-operative MRI were included
for sensitivity purposes, median overall survival was
comparable (19.0 months, 15.9–22.1 months), thus mak-
ing systematic distortion of outcome data by omission of
these patients unlikely. Median follow up for survival was
24.0 months.
Outcome stratiﬁed by resection status
Effect of pre-operative factors on extent of resection
To assess whether patient-dependent factors affected
extent of resection, which would confound interpretation
of outcome data, pre-operative patient (age, KPS) and
tumor characteristics (e.g. size, location, extent of edema)
that might have affected the decision or ability to perform
more or less extensive resections were analyzed. Location
was substratiﬁed by the factors hemisphere, frontal,
temporal, parietal, occipital location, whether more than
one brain lobe was involved, whether contrast-enhancing
tumor reached the ventricle, and by eloquence. The last
was the assessment of the surgeon based on proximity or
inﬁltration of language, motor or visual cortex, or asso-
ciated tracts. In multivariate analysis (Table 1), only the
extent of associated t2 signal abnormality (‘‘edema’’,
deﬁned as none, B2o r [2 cm) was a signiﬁcant predic-
tive factor for the extent of resection (OR 0.376, 95% CI:
0.153–0.924, p = 0.033).
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The median time from the date of resection to initiation of
radiochemotherapy was 28 days (mean: 30 days) and the
median duration of radiotherapy was 44 days (mean:
44.4 days; Supplementary Table 1), which was similar to
the duration of concomitant chemotherapy with tem-
ozolomide (median: 44 days, mean: 43.9 days). For 77
patients the initial dose of 150 mg/m
2 was increased to
200 mg/m
2.
Stratiﬁcation of patients by residual tumor load revealed
no differences concerning radiotherapy and concomitant
chemotherapy, either regarding timing or dose. However,
in the adjuvant phase of chemotherapy, patients with
complete resections received more cycles of temozolomide
(p = 0.004; Supplementary Table 3) with 38.6% of
patients with residual tumor completing six cycles in
comparison with 60.3% of patients without residual tumor.
Progression-free survival and overall survival
In univariate analysis, residual tumor on post-operative
MRI, KPS, and pre-operative tumor size were predictors of
survival. In multivariate analysis, only age and residual
tumor were signiﬁcant (Table 2). Extent of associated t2
signal abnormality (‘‘edema’’), the only factor indepen-
dently associated with extent of resection, was not pre-
dictive of survival.
Progression-free and overall survival were investigated
separately in the 107 per-protocol patients with less than
1.5 cm of residual tumor on post-operative MRI, stratiﬁed
by 0 (n = 75) vs.[0t oB1.5 cm (n = 32) residual tumor
diameters.
Progression-free survival was 13.5 months (9.9–17.1)
for patients with residual tumor of up to 1.5 cm in diameter
and 18.7 months (16.3–21.3, p = 0.058; Fig. 1) for
patients without residual contrast-enhancing tumor. With
residual tumor diameters of[1.5 cm, progression-free
survival was shorter (8.5 months, 6.2–10.9, overall
p\0.001, Fig. 1).
Median follow-up duration for survival was
24.0 months. Median overall survival surpassed the follow-
up period for patients without residual enhancing tumor,
with a mean survival at the time of ﬁnal assessment of
23.6 months (range: 21.4–25.8 months). Median survival
was 16.9 months (range 13.3–20.5 months, p = 0.039) for
patients with residual contrast-enhancing tumor of[0
to B1.5 cm diameter. In comparison patients with[1.5 cm
residual tumor diameter did worse (13.9 months; range:
10.3–17.5, overall p\0.001, Fig. 2).
MGMT promoter methylation
MGMT promoter methylation status was determined for 79
of 143 patients. Methylated promoter was found in 29
patients (36.7%) and unmethylated promoter in 50 patients
Table 1 Factors predicting the extent of resection of enhancing tumor (n = 143)
Factor Univariate Multivariate
OR 95% CI p OR 95% CI p
Right hemisphere
a 1.705 0.874–3.328 0.118 0.800 0.031–20.78 0.89
Left hemisphere
a 0.581 0.297–1.138 0.113 0.316 0.012–8.243 0.48
Frontal location
a 1.042 0.492–2.206 0.914 0.234 0.039–1.409 0.11
Occipital location
a 1.107 0.460–2.664 0.820 0.877 0.210–3.656 0.86
Parietal location
a 1.207 0.562–2.591 0.629 0.857 0.226–3.252 0.820
Temporal location
a 0.667 0.344–1.295 0.232 0.250 0.056–1.124 0.071
Tumor restricted to single lobe
a 1.977 0.453–8.623 0.364 3932 0.617–25.038 0.15
Midline shift
a 0.555 0.281–1.094 0.089 0.452 0.130–1.567 0.21
In eloquent region
a, c 1.092 0.559–2.134 0.796 1313 0.479–3.598 0.6
Contrast enhancement reaches ventricle
a 0.396 0.198–0.794 0.009 0.403 0.141–1.158 0.091
Extent of cerebral edema
b 0.559 0.309–1.010 0.054 0.376 0.153–0.924 0.033
Tumor size
d 1.368 1.071–1.746 0.012 1172 0.763–1.798 0.47
Age
d 0.997 0.968–1.027 0.589 0.989 0.947–1.033 0.62
Gender
a 1.025 0.519–2.022 0.944 1468 0.542–3.972 0.45
Pre-OP KPS
a 0.940 0.487–1.814 0.854 0.804 0.328–1.973 0.63
a Category
b None, B2 cm,[2c m
c Motor, language, visual (as assessed by surgeon)
d Continuous
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123(63.3%). Median overall survival of patients with unme-
thylated tumors was 16.6 months (95% CI: 13.8–19. 3).
Median survival was not reached for patients with meth-
ylated tumors (mean survival estimated at the end of the
observation period: 26.4 months; 24.5–28.3, p = 0.0005,
Fig. 3a). Patients with methylated tumors and complete
resection tended to have the best survival (median not
reached, mean: 27.6 months, 95% CI: 26.3–29.0 months),
whereas patients with MGMT unmethylated tumors and
incomplete resection did worst (median 13.9 months,
10.2–17.5 months, p = 0.000), as is apparent from Fig. 3b.
Both methylation status and extent of resection were
independently related to survival (MGMT promoter
methylation: p = 0.000, HR = 4.40, 95% CI: 1.93–10.1;
extent of resection: p = 0.009, HR = 2.37, 1.24–4.50).
Discussion
This was a prospective cohort study designed to test the
effect of extensive cytoreductive surgery for glioblastoma
when combined with temozolomide radiochemotherapy
followed by adjuvant temozolomide. The question is
important, because extensive cytoreductive surgery for
glioblastoma would entail unnecessary risks if concomitant
radiochemotherapy were effective for small volumes of
residual tumor. On the other hand, it may well be that
radiochemotherapy followed by adjuvant temozolomide is
more effective when all contrast-enhancing tumor is
removed surgically. One explanation may be that enhanc-
ing regions of malignant glioma on MRI are hypoxic.
Hypoxia is associated with aggressive growth and poor
response to treatment, including radiotherapy [14, 15].
Hypoxia affects tumor cells by activating genes involved in
Table 2 Univariate and
multivariate analysis of factors
predicting survival (n = 143)
a Category
b Continuous
c Motor, language, visual
(as assessed by surgeon)
d None, B2 cm,[2c m
Factor Univariate
HR
Univariate p Multivariate
HR
Multivariate p
Residual tumor
a (0; B1.5 cm;[1.5 cm) 2.285 0.000 3.097 0.000
Age
b 1.014 0.126 1.027 0.045
KPS
a 1.576 0.022 1.495 0.105
Pre-OP tumor size
b 1.196 0.008 1.125 0.226
Involvement of C2 lobes
a 1.227 0.359 1.168 0.563
Right hemisphere
a 0.969 0.878 – –
Left hemisphere
a 1.164 0.465 – –
Frontal location
a 1.246 0.341 – –
Occipital location
a 0.661 0.217 – –
Parietal location
a 0.943 0.799 – –
Temporal location
a 1.177 0.429 – –
Eloquent location
a, c 0.972 0.892 0.921 0.767
Cerebral edema
b, d 1.161 0.438 1.233 0.422
Fig. 1 Progression-free survival (n = 143), stratiﬁed by enhancing
residual glioblastoma loads determined in accordance with RECIST
criteria (p\0.001)
Fig. 2 Overall survival (n = 143), stratiﬁed by enhancing residual
glioblastoma loads determined in accordance with RECIST criteria
(p\0.001)
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123the adaptation to hypoxic stress, an important aspect of
cancer prognosis [16]. Needle electrode studies have
shown that oxygenation is lower in glioblastoma than in the
surrounding brain tissue [17] and perinecrotic regions in
glioblastoma are known to up-regulate hypoxia-inducible
factor (HIF) signaling [18] and stain positive for the
injectable hypoxia marker EF5 (2-(2-nitro-1H-imidazol-1-
yl)-N-(2,2,3,3,3-pentaﬂuoropropyl)acetamide) [16]. Exten-
sive cytoreduction is likely to remove the central core of
resilient, hypoxic, proliferative cells and some of the con-
trast-enhancing migratory cells in the marginal region,
achieving rapid tumor cell removal and thus minimizing
the target for adjuvant therapy [19].
We chose a prospective cohort study to address the
question of how outcome of radiochemotherapy is related
to the extent of resection. Non-randomized cohorts, how-
ever, suffer the disadvantage of selection effects for the
extent of resection, i.e. differences of resection status
dependent on age, tumor location, or KPS, that could
confound interpretation. To this end, it has been questioned
whether retrospective surgical cohorts were adequately
balanced by known prognostic factors such as age and
Karnofsky performance score (KPS) [20]. Studies in which
the distribution of such factors was assessed revealed that
more extensive resection was achieved for younger patients
or patients with high KPS scores [1, 6, 21]. Moreover,
small and superﬁcially located tumors are more likely to
undergo extensive resection, and such tumors may intrin-
sically have a better prognosis [22, 23]. We therefore
conceived our study as suggested by Hess [20], who argued
that ‘‘In the absence of randomized experiments with well-
deﬁned protocols for aggressive and conservative surgery,
well-planned and carefully executed prospective observa-
tional studies are needed’’.
To minimize the effect of patient-dependent factors, for
example age, tumor location, tumor size, etc., on the extent
of resection, we attempted to limit inclusion to patients with
no or small residual tumor loads with a diameter of less than
1.5 cm according to RECIST, based on assessment by sur-
geons. The reason for using RECIST criteria rather than
two-dimensional (McDonalds) or three-dimensional assess-
ments was to simplify, as far as possible, measurement of
small residual tumors in this uncontrolled study. Several
studies have demonstrated good concordance among
RECIST, two-dimensional, and three-dimensional mea-
surements in gliomas [9–11]. Our objective was to include
patients with no or minimal residual tumor. In our analysis
from the randomized ALA study, median tumor volumes of
1.5 ccm were associated with signiﬁcantly worse survival
[1]. We converted this volume into a diameter (1.43 cm)
which we rounded to give 1.5 cm, as used to deﬁne upper
volume of ‘‘small residual tumor’’ in this study.
Nevertheless, we found central image review to reveal a
number of patients with larger residual tumor loads, result-
ing in our subdivision of patients cohorts with no residual
tumor, those with residual tumor less than 1.5 cm in diam-
eter, and those with residual tumor more than[1.5 cm.
Analysis of factors that might have resulted in different
extent of resection found it to be affected by the extent of
cerebral edema, as assessed by t2 signal abnormality. Edema
was not a prognostic factor for progression-free or overall
survival and thus did not seem to confound interpretation of
the effect of resection on survival. Therefore, our strategy of
minimizing bias created by different patient-dependent fac-
tors, for example age, tumor location, KPS, tumor size, and
others, on the extent of surgery seemed effective and
enabled more rigorous conclusions regarding the beneﬁt of
cytoreductive surgery than possibly afforded by other stud-
ies [2, 3, 6, 22, 24–28]. However, the conclusion of a
missing effect of these known prognostic factors is only
valid for our cohorts, which are subselections of patients.
Age and proximity of tumor to eloquent brain, especially,
have been identiﬁed as independent factors affecting extent
of resection in more unselected series [29].
Fig. 3 a Patients stratiﬁed by MGMT status (MGMT ?, methylated
MGMT promoter; MGMT -, unmethylated MGMT promoter;
p = 0.001) (n = 79), b Patients stratiﬁed by resection and MGMT
promoter methylation (No res, no residual tumor; Res, residual tumor;
MGMT ?, methylated MGMT promoter; MGMT -, unmethylated
MGMT promoter; overall p = 0.0005) (n = 79)
94 J Neurooncol (2012) 108:89–97
123The strategy of including only patients with small
residual tumor loads also resulted in adjuvant therapy being
very similar when comparing resection groups, with the
exception of the number of cycles of adjuvant temozolo-
mide chemotherapy. In our opinion, it is unlikely that this
difference would have a detectable effect on survival.
Rather, because documentation of therapy was concluded
with tumor progression, and patients with residual tumor
had early progression, we assume that the differences in the
number of cycles are an indicator of prognosis.
The conclusions from our analysis regarding progres-
sion-free survival are, however, weakened by the lack of
bioptical conﬁrmation, and may be confounded by
pseudoprogression, which is observed in 20 to 30% of
patients [30]. Because ours was an observational study,
therapeutic decisions based on the perception of progres-
sion were at the discretion of the individual center thera-
pist. However, pseudoprogression usually occurs during
the ﬁrst three months after radiochemotherapy, and radio-
logical progression in our cohort was observed mostly after
this time. Second, the differences between survival were
also signiﬁcant. Also, there was no obligation of partici-
pating surgeons to submit tissue for reference histological
assessment and central determination of MGMT promoter
methylation, again because of the observational nature of
our study. This weakens some of our conclusions on the
interaction between this molecular predictor and resection
status.
Our analysis of overall survival revealed that the cohort
of patients without residual enhancing tumor lived longer
than patients with enhancing residual tumor, even when
comparing no residual with small residual tumor loads
(B1.5 cm diameter). In multivariate analysis, resection was
independently predictive of survival. Taken together, our
observations suggest a beneﬁcial effect of optimum
resection on radiochemotherapy.
Survival in our cohorts was slightly higher than in
the resection cohort from the EORTC 26981 study [5]
(median: 18.8 months for patients with ‘‘complete’’
resections, and 13.5 months for incomplete resections). In
this study, assessment of completeness was not based on
imaging but on surgeons’ judgement, which overestimates
resection [6]. A more recent phase II study [31] found a
PFS of 7.6 months and a OS of 21.1 months in a historical
control cohort of glioblastoma patients from UCLA
treated by surgery and adjuvant temozolomide radioche-
motherapy. However, the latter study did not stratify
outcome data by radiological extent of resection, so the
effect of resection on the efﬁcacy of radiochemotherapy
was not determined. Furthermore, 21% of patients were
reported to have had biopsies, 36% subtotal and 43%
gross total resections, again making a comparison with
our cohort difﬁcult.
Compared with the EORTC 26981 study [4], no par-
ticular differences were noted in our cohort regarding
radiotherapy (dose, duration) or duration of concomitant
therapy and number of cycles of adjuvant radiochemo-
therapy. In the EORTC 26981 study, duration of
concomitant therapy was 42 days (this study 44 days);
toxic effects were observed in 5% of patients (this study:
7.2% with grade III or IV leukopenia or thrombopenia),
median number of adjuvant cycles was three (this study
four cycles), 47% of patients completed six cycles (this
study 47.8%), with the exception of dose escalation to
200 mg/m
2, which was implemented less frequently for
patients in our study (54% vs. 67% of patients in the
EORTC study).
We found that MGMT promoter methylation and extent
of resection were independent predictors of survival. In the
subgroup of patients with MGMT promoter methylated
tumors and complete resections in our study, median
survival was not reached during the observation period.
Mean survival within the observation period was
27.3 months (95% CI: 25.6–28.9). MGMT promoter
methylation also seemed prognostic for patients with
incomplete resections, although the number of patients
with incomplete resection and promoter methylation was
too small to detect statistical signiﬁcance.
Conclusions
This observational cohort study supports the importance of
cytoreductive therapy for adjuvant temozolomide radio-
chemotherapy in the treatment of glioblastoma. Thus,
surgeons should still attempt to achieve the highest extent
of resection, preferably of all contrast-enhancing tumor if
safely possible. The prognostic effect of MGMT promoter
methylation status seems to be independent of resection,
and patients with promoter methylation have the best
prognosis, in particular when the entire contrast-enhancing
tumor mass is removed.
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